Adjuvant Ipilimumab Improves Recurrence-Free Survival of High-Risk Stage 3 Melanoma

Share this content:
In patients with completely resected high-risk stage 3 melanoma, adjuvant ipilimumab significantly improved RFS.
In patients with completely resected high-risk stage 3 melanoma, adjuvant ipilimumab significantly improved RFS.

Adjuvant ipilimumab significantly improved recurrence-free survival for patients with completely resected high-risk stage 3 melanoma, a study published in the journal The Lancet Oncology has shown.1

Researchers sought to evaluate ipilimumab in the adjuvant setting for patients with completely resected stage 3 melanoma at high risk of recurrence.

For the international, double-blind, phase III trial, researchers enrolled 951 patients and randomly assigned them 1:1 to ipilimumab 10 mg/kg IV or placebo every 3 weeks for four doses, then every 3 months for up to 3 years.1

Results showed that at a median follow-up of 2.74 years, there were 234 recurrence-free survival events in the ipilimumab group versus 294 in the placebo group.

Researchers found a median recurrence-free survival of 26.1 months (95% CI: 19.3-39.3) and 17.1 months (95% CI: 13.4-21.6) in the ipilimumab and placebo groups, respectively.

RELATED: Nivolumab Safer, More Effective Than Chemo for Advanced Melanoma

In addition, the study showed that the 3-year recurrence-free survival was 46.5% (95% CI: 41.5-51.3) in the ipilimumab group compared with 34.8% (95% CI: 30.1-39.5) in the placebo group.1

In regard to safety, the most common grade 3 to 4 adverse events associated with ipilimumab use were diarrhea (10%), colitis (~8%), increased alanine transaminase (5%), increased aspartate transaminase (~5%), and hypophysitis (~6%).

The most common immune-mediated adverse reactions included diarrhea (10%), colitis (~8%), elevated liver function enzymes (5%), hypophysitis (~6%), and dermatological side effects (4%).1

Page 1 of 2

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs